Bromfenac

Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

PRevention of Macular EDema After Cataract Surgery

Effectiveness of Periocular Drug Injection in CATaract Surgery

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

Control of Pain in Intravitreal Injections Using Topical NSAIDs

Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery

Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy